Cargando…
A novel ruthenium (II)-derived organometallic compound, TQ-6, potently inhibits platelet aggregation: Ex vivo and in vivo studies
Arterial thrombosis plays a key role in cardiovascular diseases. Hence, developing more effective antithrombotic agents is necessary. We designed a ruthenium (II)-derived complex, [Ru(η(6)-cymene)2-(1H-benzoimidazol-2-yl)-quinoline Cl]BF(4) (TQ-6), as a new antiplatelet drug. TQ-6 (0.3 µM) exhibited...
Autores principales: | Hsia, Chih-Hsuan, Velusamy, Marappan, Sheu, Joen-Rong, Khamrang, Themmila, Jayakumar, Thanasekaran, Lu, Wan-Jung, Lin, Kuan-Hung, Chang, Chao-Chien |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573325/ https://www.ncbi.nlm.nih.gov/pubmed/28842683 http://dx.doi.org/10.1038/s41598-017-09695-z |
Ejemplares similares
-
Author Correction: A novel ruthenium (II)-derived organometallic compound, TQ-6, potently inhibits platelet aggregation: Ex vivo and in vivo studies
por: Hsia, Chih-Hsuan, et al.
Publicado: (2020) -
Synthetic Ruthenium Complex TQ-6 Potently Recovers Cerebral Ischemic Stroke: Attenuation of Microglia and Platelet Activation
por: Hsia, Chih-Hsuan, et al.
Publicado: (2020) -
Antiplatelet Activity of a Newly Synthesized Novel Ruthenium (II): A Potential Role for Akt/JNK Signaling
por: Khamrang, Themmila, et al.
Publicado: (2017) -
Possible Molecular Targets of Novel Ruthenium Complexes in Antiplatelet Therapy
por: Jayakumar, Thanasekaran, et al.
Publicado: (2018) -
Ir-6: A Novel Iridium (III) Organometallic Derivative for Inhibition of Human Platelet Activation
por: Shyu, Ren-Shi, et al.
Publicado: (2018)